Risk of tuberculosis in patients treated with anti‐tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden

By  

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (ELECTRONIC), Vol. 18, Iss. 3, 2015-03 ,pp. : 323-330

John Wiley & Sons Inc

Access to resources Recommend Favorite

Factors Affecting the Tuberculosis Risk in Patients Receiving Anti-Tumor Necrosis Factor-α Treatment

By  

Respiration, Vol. 90, Iss. 3, 2015-0 ,pp. : 191-198

Karger

Access to resources Recommend Favorite

Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti‐tumor necrosis factor treatment. Part 1: Risk assessment

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 33, Iss. 1, 2018-01 ,pp. : 20-29

John Wiley & Sons Inc

Access to resources Recommend Favorite

Medication Persistence of Disease‐Modifying Antirheumatic Drugs and Anti–Tumor Necrosis Factor Agents in a Cohort of Patients With Rheumatoid Arthritis in Brazil

By  

ARTHRITIS CARE AND RESEARCH, Vol. 68, Iss. 10, 2016-10 ,pp. : 1489-1496

John Wiley & Sons Inc

Access to resources Recommend Favorite

Total cholesterol, lipoprotein, and triglyceride levels in tumor necrosis factor inhibitor‐treated patients with psoriasis, psoriatic arthritis, or rheumatoid arthritis

By  

INTERNATIONAL JOURNAL OF DERMATOLOGY, Vol. 11-9059, Iss. 10, 2015-10 ,pp. : e442-e445

John Wiley & Sons Inc

Access to resources Recommend Favorite